Abstract
Ureaplasma urealyticum is relatively common in the respiratory tract of very low birth weight infants and has been hypothesized to be involved in the development of chronic lung disease. The purpose of this study was to investigate whether U. urealyticum could stimulate macrophages to produce proinflammatory cytokines in vitro, which are early pathologic changes in the lung during the development of chronic lung disease. A human monocytic cell line (THP-1) differentiated to macrophages, a rat alveolar macrophage cell line (Nr8383), and human lung macrophages from tracheobronchial aspirate fluid in preterm infants were exposed to U. urealyticum antigen for 24 h. The protein levels of human IL-6, tumor necrosis factor-α (TNF-α), and rat TNF-α were measured with ELISA. Rat IL-6 was analyzed with a specific bioassay. The mRNA levels of these cytokines were detected by reverse transcriptase-PCR. The production of TNF-α and IL-6 increased after stimulation with U. urealyticum in both the human and rat macrophage cell lines. In tracheobronchial aspirate fluid macrophages, U. urealyticum increased the production of TNF-α from 14 to 84% and IL-6 from 46 to 268% above control levels. U. urealyticum also induced gene expression of TNF-α and IL-6. In conclusion, U. urealyticum could be an important factor in the development of chronic lung disease because of its ability to induce alveolar macrophage proinflammatory cytokine production.
Similar content being viewed by others
Main
CLD is a major problem in the care of very low birth weight infants (1). Small preterm neonates with immature lungs who are treated with mechanical ventilation and oxygen have a high risk of experiencing CLD (2–4). This disease is typified by an initial increase in the number of macrophages and polymorphonuclear lymphocytes and high levels of proinflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-8) in TAF (5, 6). These cytokines induce the inflammatory response seen in CLD. We found that the TAF level of IL-6 and TNF-α already at d 2 and 3 could predict which infants would later develop CLD (7). In later stages, lung fibrosis often follows, leading to death or long-term oxygen supplementation (7, 8).
Ureaplasma urealyticum can be found in the genital tract of 40–80% of women of child-bearing ages (9). There is some evidence supporting the hypothesis that vertically transmitted colonization and infection with U. urealyticum is an important risk factor for CLD (8, 10, 11), possibly by inducing a cytokine-mediated inflammation. However, the contribution of U. urealyticum to the development of CLD is still controversial (9). U. urealyticum has been isolated from blood, cerebrospinal fluid, TAF, and lung tissue (12), and evidence exists that it can cause invasive diseases in preterm neonates. Respiratory tract colonization has been associated with higher incidence of pneumonia (13), respiratory distress syndrome, intraventricular hemorrhage, and CLD (14). Experimental colonization of premature baboons with U. urealyticum caused an acute bronchiolitis with epithelial ulceration and polymorphonuclear infiltration (15). Newborn mice inoculated with U. urealyticum developed an acute interstitial pneumonia (16). These findings suggest that U. urealyticum may elicit an inflammatory response also in preterm infants.
We have investigated the potential pulmonary pathogenicity of U. urealyticum in vitro. We studied whether a human monocytic cell line, differentiated to macrophages, a rat alveolar macrophage cell line, and premature human infant lung macrophages could produce TNF-α and IL-6 in direct response to U. urealyticum at the mRNA and protein levels.
METHODS
Cell culture
Cell line.
The human monocytic cell line (THP-1; American Type Culture Collection, Rockville, MD, U.S.A.) was maintained in RPMI 1640 medium (Sigma Chemical Co, St. Louis, MO, U.S.A.) supplemented with 2 mM l-glutamine (Sigma), 5 mM mercaptoethanol, 10 mM HEPES (GibcoBRL, Gaithersburg, MD, U.S.A), and 10% heat-inactivated fetal bovine serum Myclone (GibcoBRL) at 37°C, 5% CO2. Before cells were used, they were split and seeded in fresh medium for 48 h and then differentiated with PMA (Sigma) at 10−8 M with 5 × 105 cells/mL in Teflon-coated bottles for 48 h. To confirm the population of macrophages, flow cytometry analysis was performed. The expression of macrophage-specific cell surface antigens showed that 96.2% of cells expressed CD14 and CD45, and 99.9% of cells expressed HLA-DR, indicating a full differentiation of macrophages. The rat alveolar macrophage cell line (Nr8383) (American Type Culture Collection) was maintained in Ham's F-12 medium (GibcoBRL) and supplemented with 15% heat-inactivated fetal bovine serum Myclone (GibcoBRL).
Human TAF macrophages.
Premature infant lung macrophages were obtained from four patients who were receiving mechanical ventilation. The clinical data for the patients are shown in Table 1. The aspirates were obtained at times when routine endotracheal suctioning was performed as follows: 0.5 mL of 0.9% saline solution was instilled into the endotracheal tube. The infant was then reconnected to the ventilator. After the ventilator was disconnected, the suction catheter was inserted past the tip of the endotracheal tube. Aspiration was then performed during the withdrawal of the catheter. After this, the catheter was flushed with a further 0.5 mL of 0.9% saline solution into a sterile specimen trap. Then the TAF was filtered through a special cell strainer (Falcon, Franklin Lakes, NJ, U.S.A.) and centrifuged, and the supernatant was discarded. The cells were then cultured in 96-microwell plates (Costar, Cambridge, MA, U.S.A.) at 5 × 105 cells/mL in RPMI 1640 medium with 2 mM l-glutamine, 10% heat-inactivated fetal bovine serum Myclone (GibcoBRL), and penicillin (100 U/mL)–streptomycin (100 μg/mL; Sigma). Macrophages were left to adhere to the plastic during a 2-h preincubation at 37°C, 5% CO2, and the supernatant together with nonadhesive cells was discarded. This part of the study was approved by the ethical committee of the Karolinska Hospital, and the parents gave their informed consent.
Preparation of U.
urealyticum antigen
U. urealyticum serotype standard strain 8 (T960; ATCC) was cultured at 37°C in 1.5 L of Ureaplasma broth medium containing 22.5 g/L of trypticase soy broth; 16.5% horse serum; 7.5% of 25% fresh yeast extract; 0.36% urea; 380,000 U/L penicillin G; and phenol red. Cells were harvested in late log phase by centrifugation at 30,000 ×g for 90 min at 4°C. The pellet was washed three times by resuspension in PBS and centrifuged as above for 30 min. After the final wash, the Ureaplasma was resuspended in a total volume of 2 mL of PBS. The number of CCUs of the concentrated suspension was determined in duplicate by 10-fold titration in Ureaplasma broth. The remaining U. urealyticum suspension was heat-killed by incubation in a waterbath at 56°C for 20 min. Complete killing was assured by incubating 25 μL of the suspension on Ureaplasma agar as well as incubation in Ureaplasma broth without urea supplement and subsequent subculture on agar on d 1, 3, and 7. The latter procedure was used as the heat-killed suspension of U. urealyticum produced a prompt color change in Ureaplasma broth because of urease activity. The U. urealyticum antigen was stored at −80°C in 0.1-mL aliquots until used.
Antigen stimulation
Human and rat macrophages from cell lines were distributed into 24-microwell plates at a concentration of 1 × 106 cells/mL and stimulated with 100 ng/mL of LPS (Sigma) or 4 × 106 to 4 × 108 CCU/mL of U. urealyticum antigen for 24 h at 37°C and 5% CO2. For rat IL-6 and TNF-α mRNA analysis, the stimulation was continued for 4 h. As controls, the same cells were incubated with media alone. All experiments were repeated four to six times. Stimulation in human TAF macrophages was performed with U. urealyticum antigen (4 × 108 CCU/mL) and medium alone for 24 h at 37°C and 5% CO2.
Cytokine analysis
All the supernatants were collected after stimulation and stored at −70°C for analysis of cytokines. ELISA kits for human TNF-α, IL-6, and rat TNF-α were obtained from R & D System (Abingdon, Oxon, U.K.). Supernatants were used for cytokine determination by the quantitative “sandwich” ELISA technique, using MAbs specific for the tested cytokines. The limits of detection of human IL-6 and TNF-α and rat TNF-α are 0.7, 4.4, and 10 pg/mL, respectively.
Specific bioassay
Rat IL-6 bioactivity analysis was performed by a specific bioassay using an IL-6–dependent cell line–7TD1 hybridoma line as previously described (17). In brief, the cells grew in an IL-6 medium, and then the cells were starved with a lower amount of IL-6 before the experiment. The viability of the cells was 70–95%. Then cells were resuspended in the medium without IL-6 to 20000 cells/mL, and 100 μL of this suspension was added to serial dilutions of samples in the same volume. A recombinant mouse IL-6 (Genzyme; Novakemi AB, Stockholm, Sweden) was used as a standard. After 72 h at 37°C in 5% CO2 incubation, the cultures were pulsed with 1 μCi of [3H]thymidine in 10 μL of saline solution, and further incubated for 6 h. The culture was then harvested onto fiberglass strips. Filter strips were dried and punched into vials, and scintillation liquid was added. The radioactivity was determined. Calculation of the IL-6 concentration in the samples was performed referring to the standard curve.
RT-PCR
Total RNA was extracted from 4 × 106 cells with RNAzolB (Biotecx Laboratories; Houston, TX, U.S.A.) after the different treatments. The cells were suspended in 1 mL of ice-cold RNAzolB, and total RNA was extracted according to the manufacturer's instructions. The final RNA pellet was air-dried, and the RNA was resuspended in 20 μL of diethyl-pyrocarbonate–treated water; 10 μL was used for spectrophotometric determination of the RNA concentration at 260 nm, and quality was determined by assessing the 230- to 320-nm profile. The remaining 10 μL was stored at −70°C.
First-strand cDNA synthesis of total RNA was performed using SuperScript RNase H− Reverse Transcriptase (GibcoBRL) and random hexamer primers [pd(N)6; Amersham Pharmacia Biotech, Uppsala, Sweden]. In brief, 1 μg of RNA together with 100 pmol of pd(N)6 was heated at 70°C for 10 min; then 0.1 mmol of DTT, 10 μmol of dNTP, 60 U of RNasin (Boehringer Mannheim, Mannheim, Germany), and 300 U of superscript were added, and the mixture was incubated at 45°C for 2 h.
Specific oligonucleotide primers were synthesized for human IL-6, human TNF-α (Scandinavian Gene Synthesis, Köping, Sweden), and the housekeeping gene human G3PDH (CyberGene AB, Huddinge, Sweden). The rat IL-6, TNF-α, and G3PDH primers were obtained from Innovagen (Lund, Sweden). The sequences of the 3′- and 5′-primers used are shown in Table 2.
PCR using Taq polymerase (final concentration, 0.025 U/μL; GibcoBRL) was performed in a final volume of 25 μL containing 2 μL of cDNA for TNF-α and G3PDH and 4 μL for IL-6 in a DNA Thermocycler 480 (Perkin Elmer, Norwalk, CT, U.S.A.). The other reaction constituents included MgCl2 (2 mM), dNTP (0.2 mM), PCR buffer, and 3′- and 5′-primers (0.5 μM each). PCR was conducted for 40 cycles for human IL-6, for 35 cycles for human TNF-α, and for 27 cycles for human G3PDH under the following conditions: 1 min denaturation at 94°C; 1 min annealing at 54°C for human IL-6, at 56°C for human TNF-α, and at 60°C for human G3PDH; and 1 min extension at 72°C, followed by a final extension for 5 min at 72°C and cooling down to 4°C. PCR was conducted for 40 cycles for rat IL-6 and rat TNF-α with 1 min at 94°C, 30 s at 54°C for rat IL-6 and at 58°C for rat TNF-α, and 3 min at 72°C; and for 35 cycles for rat G3PDH with 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C, followed by a final extension for 5 min at 72°C and cooling down to 4°C.
The PCR products were separated on a 1.5% agarose gel (GibcoBRL). The ethidium bromide–stained gel was photographed under UV light with the DC120 Digital Zoom Camera (Eastman Kodak Company, Rochester, NY, U.S.A.), and the net intensities of the PCR products were analyzed with the Kodak Digital Science Electrophoresis Documentation and Analysis System 120 (Eastman Kodak).
Data analysis
ELISA and bioassay data from pooled experiments were reported as means and the 95% confidence interval. Data were analyzed by t test or one-way ANOVA. Nonnormality paired data were analyzed by Wilcoxon matched pairs test. A p value of <0.05 was considered to be significant.
RESULTS
TNF-α production.
U. urealyticum antigen stimulated the production of TNF-α in the THP-1 cell line and the rat alveolar macrophage cell line in a dose-dependent manner (Fig. 1, A and B). The highest concentration of U. urealyticum (4 × 108 CCU/mL) produced levels of TNF-α in the THP-1 cell line close to those with 100 ng/mL LPS. In the rat alveolar macrophage cell line, high concentrations (≥4 × 107 CCU/mL) of U. urealyticum stimulated the production of TNF-α (p < 0.05), but to much lower levels than stimulation with 100 ng/mL LPS (mean, 10,545 pg/mL).
The production of TNF-α from lung macrophages from premature infants stimulated by U. urealyticum antigen at 4 × 108 CCU/mL was studied, and the TNF-α levels with U. urealyticum stimulation were 14.4 to 84.0% higher than the unstimulated (19,554 versus 17,098 pg/mL; 3,847 versus 2,524 pg/mL; and 3,388 versus 1,841 pg/mL, referring to samples 1–3 in Table 1;p < 0.05).
IL-6 production.
U. urealyticum antigen stimulated the production of IL-6 the THP-1 cell line (Fig. 2A) and the rat alveolar macrophage cell line (Fig. 2B) in a dose-dependent way. High concentrations (≥4 × 107 CCU/mL) of U. urealyticum antigen stimulated the production of IL-6 in the THP-1 cell line, but to significantly lower levels than with 100 ng/mL LPS (632 pg/mL;p < 0.05). In the rat alveolar macrophage cell line, high concentrations (≥4 × 106 CCU/mL) of U. urealyticum antigen stimulated the production of IL-6, but to much lower levels than stimulation with 100 ng/mL LPS (mean, 62,400 pg/mL).
IL-6 production in the premature infant lung macrophages stimulated by U. urealyticum (4 × 108 CCU/mL) was studied, and the IL-6 levels of U. urealyticum stimulation were 45.5 to 268.4% higher than the unstimulated (1,259 versus 861 pg/mL; 596 versus 277 pg/mL; 5,493 versus 3,776 pg/mL; 11,836 versus 3,213 pg/mL; 80,789 versus 50,307 pg/mL, referring to samples 4–8 in Table 1;p < 0.05).
Cytokine mRNA expression.
TNF-α and IL-6 gene expression stimulated by U. urealyticum antigen (4 × 108 CCU/mL) is shown in Figure 3. In the THP-1 cell line, both IL-6 and TNF-α mRNA were induced by U. urealyticum compared with unstimulated cells (I). The ratio of net intensity of IL-6/G3PDH was 0.43 in stimulated cells and 0.13 in unstimulated cells. TNF-α/G3PDH was 1.35 in stimulated cells and 0.79 in unstimulated cells. Similar results were found in the rat alveolar macrophage cell line (II): IL-6/G3PDH was 0.35 in stimulated cells and 0.03 in unstimulated cells, and TNF-α/G3PDH was 0.65 in stimulated cells compared with 0.04 in unstimulated cells.
DISCUSSION
In this study, we found a dose-response expression of IL-6 and TNF-α protein and increased levels of IL-6 and TNF-α mRNA in vitro after stimulation of macrophages with U. urealyticum antigen. It has long been debated whether U. urealyticum is one of the pathogenic factors in the development of CLD. Increasing clinical evidence for the association of this organism with clinical disease has emerged (7, 10, 21–24), and a recent meta-analysis also supported an independent role of U. urealyticum in the development of CLD (21). Our present data support a pathogenic role for U. urealyticum.
The initial pathologic changes of CLD are typified by an increase in the number of macrophages and polymorphonuclear lymphocytes in the lung, and high TAF levels of proinflammatory cytokines (25). Preterm infants who acquire CLD demonstrate increased levels of proinflammatory cytokines and chemokines in lung lavage fluid as early as d 1 of life (7). The proinflammatory cytokine levels increase during the first week of life, reach a peak at approximately 2 wk, and remain elevated for several weeks (6, 26). We have previously found that increased levels of especially IL-6 and TNF-α are associated with the development of CLD (7). The exact mechanism explaining the correlation between the increased IL-6 levels and the development of CLD is not known. These previous findings, together with the present results, do, however, demonstrate an imbalance of the complex network of inflammatory mediators, which may lead to irreversible lung tissue destruction and fibrosis (26). Our findings support the correlation between U. urealyticum colonization and TNF-α levels in TAF previously found. However, in contrast to us, these authors found no correlation between IL-6 and U. urealyticum (27).
The human macrophage cell line was much more susceptible to Ureaplasma than the rat cell line. This interspecies difference needs to be recognized in further studies. The findings in the neonatal alveolar macrophages are of course the most interesting but come from only four different infants. These cells are already stimulated in vivo in the babies. They therefore already produced increased and, in some instances, very high cytokine levels. Still, U. urealyticum antigen could in all cases increase the cytokine production further.
There was a dose-response relationship between the concentrations of U. urealyticum and the cytokine response. It is difficult to compare in vitro bacterial concentrations with those present in vivo in neonates. Very marked differences in bacterial numbers have been found in vivo. The numbers of bacteria adhering to the airway surface might also be very different from those found in the bronchial fluid.
Much information concerning the precise role of U. urealyticum in lung disease in newborns comes from necropsy, but little is from clinical and laboratory studies of surviving babies (28, 29). Differences in host immune response, serotype pathogenicity, genetic predisposition, or other factors could affect the outcome of U. urealyticum infection (16, 30). The pathogenicity of U. urealyticum may be caused in part by its ability to produce phospholipases A and C, which can catalyze the release of arachidonic acid from membrane phospholipid (31). Arachidonic acid and its metabolites are potent lipid mediators that can induce the release of proinflammatory cytokines (32, 33). Further studies should elucidate which part of the U. urealyticum is most important in eliciting the cytokine response.
The inflammatory response caused by U. urealyticum seems to be of a type similar to that of other infectious agents. The response, however, seems to be somewhat less pronounced than that caused by bacteria of higher virulence. This gives less pronounced symptoms. The inflammation persists for a longer time, giving a high risk of developing the chronic changes of CLD.
In conclusion, we have demonstrated that U. urealyticum can stimulate macrophages to produce high levels of proinflammatory cytokines in vitro. This supports the hypothesis that U. urealyticum could be an etiological factor associated with the development of CLD in premature infants.
Abbreviations
- CLD:
-
chronic lung disease
- TAF:
-
tracheobronchial aspirate fluid
- LPS:
-
lipopolysaccharide
- RT-PCR:
-
reverse transcriptase polymerase chain reaction
- CCU:
-
color-changing units
- PMA:
-
phorbol 12-myristate 13-acetate
- TNF-α:
-
tumor necrosis factor-α
- G3PDH:
-
glyceraldehyde-3-phosphate dehydrogenase
References
Northway WH Jr 1992 Bronchopulmonary dysplasia: twenty-five years later [see comments]. Pediatrics 89: 969–973
Northway WH Jr 1990 Bronchopulmonary dysplasia: then and now. Arch Dis Child 65: 1076–1081
Robertson B 1989 The evolution of neonatal respiratory distress syndrome into chronic lung disease. Eur Respir J 3: 33s–37s
Northway WH Jr, Rosan RC, Porter DY 1967 Pulmonary disease following respirator therapy of hyaline-membrane disease. N Engl J Med 276: 357–368
Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ 1996 Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 40: 250–256
Tullus K, Noack GW, Burman LG, Nilsson R, Wretlind B, Brauner A 1996 Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. Eur J Pediatr 155: 112–116
Jonsson B, Tullus K, Brauner A, Lu Y, Noack G 1997 Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 77: F198–F201
Cassell GH, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S, Cutter GR 1988 Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet 2: 240–245
van Waarde WM, Brus F, Okken A, Kimpen JL 1997 Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 10: 886–890
Perzigian RW, Adams JT, Weiner GM, Dipietro MA, Blythe LK, Pierson CL, Faix RG 1998 Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era. Pediatr Infect Dis J 17: 620–625
Wang EE, Frayha H, Watts J, Hammerberg O, Chernesky MA, Mahony JB, Cassell GH 1988 Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity. Pediatr Infect Dis J 7: 547–551
Waites KB, Crouse DT, Cassell GH 1993 Systemic neonatal infection due to Ureaplasma urealyticum. Clin Infect Dis 17: S131–S135
Crouse DT, Odrezin GT, Cutter GR, Reese JM, Hamrick WB, Waites KB, Cassell GH 1993 Radiographic changes associated with tracheal isolation of Ureaplasma urealyticum from neonates. Clin Infect Dis 17: S122–S130
Abele-Horn M, Peters J, Genzel-Boroviczeny O, Wolff C, Zimmermann A, Gottschling W 1997 Vaginal Ureaplasma urealyticum colonization: influence on pregnancy outcome and neonatal morbidity. Infection 25: 286–291
Walsh WF, Butler J, Coalson J, Hensley D, Cassell GH, deLemos RA 1993 A primate model of Ureaplasma urealyticum infection in the premature infant with hyaline membrane disease. Clin Infect Dis 17: S158–S162
Rudd PT, Cassell GH, Waites KB, Davis JK, Duffy LB 1989 Ureaplasma urealyticum pneumonia: experimental production and demonstration of age-related susceptibility. Infect Immun 57: 918–925
Hagberg H, Gilland E, Bona E, Hanson LA, Hahin-Zoric M, Blennow M, Holst M, McRae A, Soder O 1996 Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res 40: 603–609
Pisa EK, Pisa P, Hansson M, Wigzell H 1992 OKT3-induced cytokine mRNA expression in human peripheral blood mononuclear cells measured by polymerase chain reaction. Scand J Immunol 36: 745–749
Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M 1996 Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69: 114–119
Williams CM, Coleman JW 1995 Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology 86: 244–249
Wang EE, Ohlsson A, Kellner JD 1995 Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a meta-analysis. J Pediatr 127: 640–644
Alfa MJ, Embree JE, Degagne P, Olson N, Lertzman J, Macdonald KS, Macdonald NT, Hall PF 1995 Transmission of Ureaplasma urealyticum from mothers to full and preterm infants. Pediatr Infect Dis J 14: 341–345
Abele-Horn M, Genzel-Boroviczeny O, Uhlig T, Zimmermann A, Peters J, Scholz M 1998 Ureaplasma urealyticum colonization and bronchopulmonary dysplasia: a comparative prospective multicentre study. Eur J Pediatr 157: 1004–1011
Ollikainen J, Heiskanen-Kosma T, Korppi M, Katila ML, Heinonen K 1998 Clinical relevance of Ureaplasma urealyticum colonization in preterm infants. Acta Paediatr 87: 1075–1078
Jones CA, Cayabyab RG, Kwong KY, Stotts C, Wong B, Hamdan H, Minoo P, deLemos RA 1996 Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 39: 966–975
Ozdemir A, Brown MA, Morgan WJ 1997 Markers and mediators of inflammation in neonatal lung disease. Pediatr Pulmonol 23: 292–306
Patterson AM, Taciak V, Lovchik J, Fox RE, Campbell AB, Viscardi RM 1998 Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J 17: 321–328
Waites KB, Crouse DT, Philips JB III, Canupp KC, Cassell GH 1989 Ureaplasmal pneumonia and sepsis associated with persistent pulmonary hypertension of the newborn. Pediatrics 83: 79–85
Brus F, van Waarde WM, Schoots C, Oetomo SB 1991 Fatal ureaplasmal pneumonia and sepsis in a newborn infant. Eur J Pediatr 150: 782–783
Naessens A, Foulon W, Breynaert J, Lauwers S 1988 Serotypes of Ureaplasma urealyticum isolated from normal pregnant women and patients with pregnancy complications. J Clin Microbiol 26: 319–322
De Silva NS, Quinn PA 1986 Endogenous activity of phospholipases A and C in Ureaplasma urealyticum. J Clin Microbiol 23: 354–359
Baldie G, Kaimakamis D, Rotondo D 1993 Fatty acid modulation of cytokine release from human monocytic cells. Biochim Biophys Acta 1179: 125–133
Holladay CS, Wright RM, Spangelo BL 1993 Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro : evidence for a prostacyclin-dependent mechanism. Prostaglandins Leukot Essent Fatty Acids 49: 915–922
Estler HC, Grewe M, Gaussling R, Pavlovic M, Decker K 1992 Rat tumor necrosis factor-alpha. Biol Chem Hoppe Seyler 373: 271–281
Acknowledgements
The authors thank Berit Fröysa and Yvonne Löfgren for excellent laboratory work assistance.
Author information
Authors and Affiliations
Additional information
Supported by Stiftelsen Frimurare Barnhuset, the Funds of Karolinska Institute, and Magn. Bergvalls foundation.
Rights and permissions
About this article
Cite this article
Li, YH., Brauner, A., Jonsson, B. et al. Ureaplasma urealyticum-Induced Production of Proinflammatory Cytokines by Macrophages. Pediatr Res 48, 114–119 (2000). https://doi.org/10.1203/00006450-200007000-00020
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-200007000-00020
This article is cited by
-
The Associations of Genital Mycoplasmas with Female Infertility and Adverse Pregnancy Outcomes: a Systematic Review and Meta-analysis
Reproductive Sciences (2021)
-
The association between respiratory tract Ureaplasma urealyticum colonization and severe retinopathy of prematurity in preterm infants ≤1250 g
Eye (2012)
-
Effect of HCMV IE1 protein on cytokines secretion and apoptosis of macrophages
Chinese Journal of Cancer Research (2008)
-
Down-regulation of cytokine secretion and repression of apoptosis hDaxx in macrophages
Chinese Journal of Cancer Research (2005)
-
Activation of macrophage nuclear factor-κB and induction of inducible nitric oxide synthase by LPS
Respiratory Research (2002)